BCM
ENZ

BlueCrest Capital Management’s Enzo Biochem, Inc. ENZ Stock Holding History

BlueCrest Capital Management’s Portfolio ENZ Stock Details ENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-26,562
Closed -$146K – 1884
2018
Q1 		$146K Buy
+26,562
New +$187K ﹤0.01% 1322

Other funds holding ENZ

EGA
Evermore Global Advisors Summit, New Jersey $26.3M AUM 7.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlueCrest Capital Management's ENZ Position: Q2 2018 in Review

BlueCrest Capital Management sold out of Enzo Biochem, Inc. (ENZ) in Q2 2018, closing a stake of 26,562 shares — an estimated $146K sold.

BlueCrest Capital Management first reported a position in ENZ in Q1 2018 and held it in 1 quarter. The position peaked at $146K in Q1 2018. 97 funds tracked by Wall St. Rank hold ENZ as of Q2 2018.

  • BlueCrest Capital Management reported no remaining Enzo Biochem, Inc. position as of Q2 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 26,562 Enzo Biochem, Inc. shares in Q2 2018, an estimated $146K.
  • BlueCrest Capital Management first reported a position in Enzo Biochem, Inc. in Q1 2018 and held it in 1 quarter.
  • BlueCrest Capital Management's Enzo Biochem, Inc. position peaked at $146K in Q1 2018.
  • 97 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q2 2018.

Based on BlueCrest Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.